#South Korea #Seoul #Hypertension #Sky Labs #CART BP pro

Introduction

The landscape of hypertension management has dramatically evolved with the introduction of cuffless blood pressure monitoring technology. Sky Labs, an innovative healthcare company based in South Korea, has made headlines with its newest product, the CART BP pro—a ring-type blood pressure monitor that has been officially integrated into the latest 2026 Korean Society of Hypertension Guidelines for the Management of Hypertension. This monumental step not only underscores the effectiveness of cuffless devices but also positions South Korea at the forefront of global health innovation.

The Significance of Cuffless Monitoring

Traditionally, measuring blood pressure has involved cumbersome cuffs that compress the arm, often leading to discomfort and inaccuracies in everyday situations. The CART BP pro operates differently; it utilizes advanced photoplethysmography (PPG) technology, allowing it to measure blood pressure non-invasively and unobtrusively on the finger. This breakthrough has made it the first ring-type device to be recommended by the Korean Society of Hypertension, setting a precedent in clinical practice worldwide.

Key Findings from the Guidelines

At the recent Korean Society of Cardiology conference, the society presented the updated hypertension guidelines, formally affirming the need for innovative devices for out-of-office blood pressure measurement. The Korean Society of Hypertension classified the cuffless monitor under Class IIb, highlighting its potential importance in clinical settings.

According to the society, past hesitations by major academic bodies in the US and Europe about incorporating cuffless devices were mainly due to concerns regarding validation and accuracy. However, the CART BP pro has demonstrated reliable correlation with traditional auscultatory methods, proving its potential as a standard in hypertension monitoring. This is pivotal as hypertension often goes undetected, and this device may fill critical gaps in patient assessment.

Addressing undiagnosed Hypertension

The revised guidelines emphasize the increasing need for continuous blood pressure monitoring, especially among those with prehypertension and chronic conditions such as diabetes. The urgency for consistent monitoring stems from the identification of conditions like masked hypertension, nocturnal hypertension, and morning hypertension—all of which often lead to serious cardiovascular events if not monitored properly. The guidelines urge clinicians to consider ambulatory blood pressure monitoring as essential for these high-risk groups, advocating for devices like the CART BP pro to accurately track fluctuations in blood pressure throughout the day and night.

Clinical Validation and Adoption

The CART BP pro has successfully met international standards for accuracy, as evidenced in various clinical trials, demonstrating a mean error of less than 5 mmHg in comparison to traditional 24-hour ambulatory blood pressure monitoring. Additionally, the significant adoption rate since its introduction in June 2024, with over 250,000 prescriptions issued at approximately 1,920 medical facilities across South Korea, speaks to its effectiveness and reliability.

Jack ByungHwan Lee, CEO of Sky Labs, states, “The inclusion of CART BP pro in the KSH guidelines is a monumental indication of Korea's leading role in establishing global standards for cuffless blood pressure technology.” The success of this technology is expected to capture attention not only domestically but internationally, with plans to expand regulatory approvals in other territories.

Conclusion

With the advent of technologies like the CART BP pro, hypertension management is moving towards a more patient-centric approach, emphasizing comfort, accuracy, and continuous monitoring. The integration into official guidelines opens the floodgates for more healthcare institutions to adopt cuffless technologies, potentially revolutionizing how hypertension is diagnosed and treated globally. Metrics showing improvements in patient outcomes will surely galvanize further research and innovation in the healthcare sector, propelling it into a new era of medical advances.